文献速递银屑病与炎症性皮肤病

受孕及妊娠期生物制剂暴露的系统综述

Exposure to biological therapies during conception and pregnancy: a systematic review.
PubMed 文献 · Br J Dermatol · 2017-12-14

该系统综述评估了银屑病治疗相关生物制剂在受孕和/或妊娠期的安全性。缺乏银屑病及IL-17/IL-12/23抑制剂相关研究。

要点

  • TNFi暴露与先天畸形和早产风险呈上升趋势但未达统计学显著。
  • 研究异质性大且缺乏银屑病及IL-17/IL-12/23抑制剂数据。
  • 咨询时需权衡未治疗的重度银屑病对妊娠和母体健康的影响。

核心结论

  • TNFi暴露与先天畸形和早产风险呈上升趋势,但因研究异质性及混杂因素未调整,因果关联尚不确定。
  • 缺乏银屑病受孕/妊娠期TNFi暴露以及IL-17和IL-12/23拮抗剂的相关研究。

研究设计与样本

  • 系统综述,检索PubMed、MEDLINE、Embase和Cochrane数据库,纳入多变量调整研究。
  • 纳入4项人群队列研究,共1300名在妊娠前3个月或妊娠前3个月内暴露于TNF-α抑制剂的女性。

主要发现

  • 上述趋势并非在所有研究中均达到统计学显著。

临床怎么用

  • 咨询时需权衡TNFi暴露的潜在风险与未治疗的重度银屑病对受孕、妊娠及母体健康的影响。
  • 持续通过注册登记进行药物警戒以填补证据空白。

局限性

  • 研究异质性、比较队列差异、未充分调整重要混杂变量(如联合治疗)以及缺乏共同畸形谱。
  • 无研究专门探讨银屑病受孕和/或妊娠期TNFi暴露,也无IL-17和IL-12/23拮抗剂在任何适应症中的研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biological therapies are effective treatments for psoriasis and are often prescribed to women of child-bearing age. OBJECTIVES: To evaluate the safety of biological therapy in conception and/or pregnancy. METHODS: We performed a systematic review of PubMed, MEDLINE, Embase and Cochrane databases for multivariate-adjusted studies of women exposed to biologics relevant to the treatment of psoriasis during conception and/or pregnancy. RESULTS: We identified four population-based cohort studies involving 1300 women exposed to tumour necrosis factor (TNF)-α inhibitors (TNFi) 3 months prior to or during the first 3 months of pregnancy. These studies showed a trend towards drug-specific harm with TNFi exposure in women with different inflammatory diseases, with an increased risk of congenital malformations [three studies; odds ratio (OR) range 1·32-1·64] and preterm birth (one study; OR 1·69, 95% confidence interval 1·10-2·60). This trend did not reach statistical significance in all studies; study heterogeneity, variation across comparator cohorts, inadequate adjustment for important confounding variables such as co-therapy, and an absence of a common constellation of malformations means there is uncertainty about the causal role of TNFi. No studies specifically addressed the effect of TNFi exposure in psoriasis during conception and/or pregnancy, or of interleukin (IL)-17 and IL-12/23 antagonists in any indication. CONCLUSIONS: When counselling women these findings must be balanced against the potential impact of untreated severe psoriasis on conception and/or pregnancy and maternal wellbeing; ongoing pharmacovigilance via registries remains essential to address this evidence gap.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Pottinger E, Woolf RT, Exton LS, et al. Exposure to biological therapies during conception and pregnancy: a systematic review. Br J Dermatol. 2017. PMID: 28718898. doi:10.1111/bjd.15802

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。